Cargando…
Realgar-induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis
KRAS is a biomarker for non-small cell lung cancer-targeted therapy, but there is currently no effective KRAS-targeting medication. Realgar is an impelling anti-cancer drug, however its significance in KRAS mutant lung cancer is uncertain. According to our findings, the IC(50) of H23 (KRAS mutant) c...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635866/ https://www.ncbi.nlm.nih.gov/pubmed/36321791 http://dx.doi.org/10.3892/ijo.2022.5447 |